Recursion was founded more than a decade ago on the idea that we could take images of cells and use these images to train artificial intelligence to understand the vast unknown biological …

Dr. Khan also helped lead Recursion’s combination with Exscientia – the largest TechBio deal of 2024 – and has expanded the Recursion OS 2.0 platform into an end-to-end engine for drug …

Oct 9, 2025 · SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, …

Explore Recursion's dynamic drug discovery pipeline. Witness the innovations and breakthroughs in our journey. Dive deeper with us today!

Embark on a career journey with Recursion. Dive into opportunities, culture, and the impact you can make. Apply to work with us today!

Nov 5, 2025 · Explore Recursion's latest blog posts on AI, automation, and molecular modeling in drug discovery. Stay informed with cutting-edge insights!

The recursion mindset is the deep belief and commitment to industrializing drug discovery through automation, algorithms, and data to deliver on our mission. This is made manifest through our …

Recursion's TechBio approach: The future of AI drug discovery In traditional drug discovery, 90% of drugs fail in clinical trials, after more than a decade in development and ~$2 billion in costs. …

Sep 1, 2017 · Stay updated with the latest press releases and news from Recursion. Dive into our achievements, announcements, and more. Explore now!

Oct 23, 2024 · For the past two and a half years following the launch of a transformational collaboration with Genentech and Roche, a team of 50 people at Recursion has had a singular …